Search Within

Chau Dang

Formats
  1. Journal Article (132)
  2. Meeting Abstract (122)
  3. Guidelines (8)
  4. Book Section (4)
  5. Review (3)
  6. Book Whole (1)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Breast Medicine Service (273)
  2. Department of Medicine (273)
  3. Solid Tumor Oncology Division (273)
  4. Survivorship Research (273)
  5. Population Sciences Research Program (119)
  6. Epidemiology and Biostatistics (93)

More Groups

People
  1. Clifford Hudis (111)
  2. Larry Norton (76)
  3. Richard Steingart (49)
  4. Anthony Yu (46)
  5. Shanu Modi (42)
  6. Sujata Patil (41)

More People

Years
  1. 2025 (4)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (18)
  5. 2021 (12)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Cancer Research (42)
  3. Breast Cancer Research and Treatment (23)
  4. Annals of Oncology (10)
  5. Clinical Breast Cancer (7)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (70)
  2. American Association for Cancer Research (50)
  3. Springer (33)
  4. Oxford University Press (22)
  5. Elsevier Inc. (16)
  6. American Medical Association (11)

More Publishers

Results (273)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The taxane limbo: How low can we go?
    Journal Article

    Hudis, C.; Dang, C.
    JNCI: Journal of the National Cancer Institute (2008)

    Fulltext@MSK | Save
  • A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Journal Article

    Dickler, M. N.; Rugo, H. S.; Eberle, C.; Brogi, E.; Caravelli, J.; Panageas, K. S.; Boyd, J.; Yeh, B.; Lake, D. E.; Dang, C.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Dose-dense chemotherapy with trastuzumab is an appropriate option
    Journal Article

    Dang, C.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Journal Article

    Dang, C.; D'Andrea, G.; Lake, D.; Sugarman, S.; Fornier, M.; Moynahan, M. E.; Gilewski, T.; Hurria, A.; Mills, N.; Troso-Sandoval, T.; more...
    Clinical Breast Cancer (2008)

    Fulltext@MSK | Save
  • Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety
    Meeting Abstract

    Dickler, M. N.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Sugarman, S.; Norton, L.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer
    Meeting Abstract

    Mcarthur, H. L.; Rugo, H.; Paulson, M.; Rourke, M.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Park, J.; more...
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save
  • Current status of the taxanes as adjuvant therapy for breast cancer
    Journal Article

    Hudis, C.; Mcarthur, H.; Dang, C.
    Breast (2007)

    Fulltext@MSK | Save
  • Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective
    Meeting Abstract

    Hurria, A.; Goldfarb, S.; Rosen, C.; Holland, J.; Zuckerman, E.; Lachs, M.; Witmer, M.; van Gorp, W.; Fornier, M.; D'Andrea, G.; more...
    Journal of the American Geriatrics Society (2006)

    Fulltext@MSK | Save
  • Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Norton, L.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save